Blood Podcast Episode Summary

Podcast: Blood Podcast
Host: American Society of Hematology
Episode: Spotlight on Acute Myeloid Leukemia
Date: October 16, 2025

Overview of Episode Theme

This bonus episode presents a deep dive into the "Spotlight Series on Acute Myeloid Leukemia (AML)", recently published in Blood journal. Associate Editor Dr. Selina Luger moderates a discussion with series authors Dr. Laura Michaels and Dr. Alexander "Sasha" Pearl. The focus is on four major clinical challenges in AML, with particular attention to treating older fit adults and FLT3-mutated disease. The conversation covers new therapeutic strategies, the significance of assessing patient fitness, the evolving landscape of targeted therapies, and the persistent difficulties posed by certain genetic mutations such as TP53.

Key Discussion Points & Insights

1. Series Overview (00:25)

• Four prominent challenges in AML treatment highlighted:
  • Approaches to FLT3-mutated AML (Dr. Pearl)
  • Clinical management in fit older adults (Dr. Michaels, Dr. Abedin, Dr. Wee)
  • Allogeneic transplant in AML patients over 70 (Dr. Walters Potter, Dr. Craddock)
  • Treatment approaches to TP53-mutant AML (Dr. Salman, Dr. Stahl)

2. Treating the Older, Fit Adult with AML

Speaker: Dr. Laura Michaels
Segment: [02:06–06:42]

• Targeted Therapy Advances:
  • Most novel AML therapeutics and clinical trials historically focused on less fit or frail patients.
    • "These include...venetoclax with a hypomethylating agent...targeted agents like IDH1/2 inhibitors, even some of the FLT3 inhibitors...trials that focused on a less fit or a more frail individual." [02:19]
  • Fit older adults often excluded from reaping benefits of newer regimens, except with liposomal daunorubicin and cytarabine.
• Patient 'Fitness' Complexity:
  • Defining 'fitness' remains inconsistently operationalized.
    • "There's been a lot of spinning of our wheels on how do we even know if somebody's fit or not." [03:11]
  • Frailty measures and geriatric assessments lack clear clinical endpoints due to scant randomized data.
• Intensive vs. Less Intensive Therapy:
  • If less toxic therapies prove as efficacious as traditional intensive regimens, the relevance of 'fitness' could decrease.
  • Prospective randomized studies, ongoing, may soon clarify this debate.
• Understanding Remission & Outcomes:
  • Assessing depth of remission in older adults is nuanced, especially those at higher risk for relapse; minimal residual disease (MRD) monitoring may be crucial.
  • Many questions remain about best practices; the article seeks to clarify unresolved challenges.
    • "A lot of questions answered, not a huge amount of answers, but it was really helpful...to identify some of the stuff you face when you’ve got a 65-year-old, very healthy person sitting in your clinic with AML." [05:28]

3. Is Transplant the Ultimate Goal for Fit Older Patients?

Speakers: Dr. Selina Luger, Dr. Laura Michaels
Segment: [05:44–06:56]

• Not always—depends on disease biology:
  • Some patients, e.g. those with core binding factor leukemias or favorable/intermediate risk by genetics, may achieve cure without transplant.
  • MRD assessment helps identify those who can potentially avoid transplant when true remission is ensured.
    • "Maybe those people can be salvaged at first relapse and therefore can avoid a transplant..." [05:57]

4. Is Immediate AML Treatment Always Necessary?

Speakers: Dr. Selina Luger, Dr. Laura Michaels
Segment: [06:42–08:03]

• Urgency of initiation is shifting:
  • "There is growing amount of data that that's not the case." [06:56]
  • Recent studies show delay in treatment often does not worsen outcomes for most patients, both in older and now younger groups.
  • Exception: those with acute clinical instability.
  • Need for rapid diagnostics to avoid unnecessary hospitalization delays.
    • "From a safety stake, I would say the great majority of patients with AML, you have time to get the foundation right." [07:41]

5. Treating TP53-Mutated AML in Older Fit Patients

Speakers: Dr. Selina Luger, Dr. Laura Michaels
Segment: [08:03–09:18]

• Treatment Paradigm:
  • Cytotoxic chemotherapy is often avoided.
  • Priority is enrollment in clinical trials; otherwise, lower-intensity regimens are considered, sometimes metronomic (less frequent) dosing.
• Remission ≠ Survival:
  • Achieving remission, even with transplant, rarely translates into significantly improved survival for these patients.
    • "Even when you can get somebody in remission with P53, that doesn't necessarily translate into an improved overall survival." [09:10]

6. Evolution in FLT3-mutated AML Treatment

Speaker: Dr. Alexander "Sasha" Pearl
Segment: [09:18–14:21]

• Historical Progress:
  • FLT3 found mutated in ~1/3 of AML patients – first targeted gene in AML.
  • Early inhibitor (midostaurin, via RATIFY trial) was non-selective; now, more potent and selective options (quizartinib, gilteritinib) are available.
    • "The Ratify study was the first example where we had a new drug approval that was for a mutationally selected population." [09:40]
• Current Strategy:
  • Multiple FLT3 inhibitors used in various settings (frontline, salvage, maintenance).
  • Modern treatment decisions are now based on extensive Phase 3 data.
  • MRD monitoring using sensitive assays for FLT3ITD can guide intensity of therapy and maintenance post-transplant.
    • "There's a number of studies that have actually shown that that's predictive of chemotherapy success, of transplant success, and also for the benefit of a FLT3 inhibitor given after transplant..." [12:28]
• Personalized Pathways:
  • Higher-quality remissions and improved survival seen; research now focuses on minimizing treatment intensity and individualizing therapy.

7. FLT3 Inhibitors for Older, Unfit AML Patients

Speakers: Dr. Selina Luger, Dr. Alexander Pearl
Segment: [14:21–16:30]

• Intensive chemotherapy plus FLT3 inhibitors does not conclusively improve survival in older patients, unlike in younger counterparts.
  • "Adding a FLT3 inhibitor to intensive chemotherapy...did not show in the subset analysis of the older patients that there was a survival advantage..." [14:49]
• Lower-intensity regimens (venetoclax + HMA) look promising but high relapse rates remain.
• Ongoing studies (e.g., MyLAMatch) are evaluating optimal sequencing and combinations with FLT3 inhibitors.

8. Contrast with TP53 – Why No “TP53 Inhibitor”?

Speakers: Dr. Selina Luger, Dr. Alexander Pearl
Segment: [16:30–18:00]

• TP53 is a tumor suppressor gene regulating DNA repair, not an activating kinase.
• No therapeutic equivalent to FLT3 inhibition; attempts at targeting misfolding, DNA repair, or immune modulation (e.g., magrolimab) have yet to deliver survival benefits.
• Remain an urgent unmet need, especially common in older AML.

9. The Search for a Next-Generation FLT3 Inhibitor

Speakers: Dr. Laura Michaels, Dr. Alexander Pearl
Segment: [18:00–21:02]

• Ideal properties: high potency, tolerability in combination regimens, clear efficacy, low toxicity, and minimized resistance.
• So far, comparative studies (e.g., midostaurin vs. gilteritinib) have not shown a clear “best in class.”
  • "It would be nice to have a drug that just was head and shoulders better than the others in terms of efficacy." [18:41]
• Tolerability is critical as maintenance therapy is prolonged.
• Resistance mechanisms involve selection for non-FLT3 leukemic clones, emergence of secondary mutations.
• Interest remains in dual-targeting drugs (e.g., against IRAK4, JAK) but value yet to be established.

Notable Quotes & Memorable Moments

• "A lot of the developments that have occurred in the AML community for patients have been specifically directed to the less fit patient."
  — Dr. Laura Michaels [02:10]
• "There's been a lot of spinning of our wheels on how do we even know if somebody's fit or not."
  — Dr. Laura Michaels [03:11]
• "From a safety stake, I would say the great majority of patients with AML, you have time to get the foundation right."
  — Dr. Laura Michaels [07:41]
• "FLT3 is essentially the first target for which we had drugs that were approved that we would use a mutation diagnosis and give the patient a targeted agent in the hopes that this would improve their outcome."
  — Dr. Alexander Pearl [09:36]
• "We know a lot more than we used to, and I'm hoping in the future we really could say this is the right way to treat the patient at every step of the way."
  — Dr. Alexander Pearl [14:17]
• "If there's any place we need progress, it's how to treat [TP53-mutant] disease."
  — Dr. Laura Michaels [08:49]

Key Timestamps

| Segment | Description | |---------|------------------------------------------------------------------------------------------------| | 00:25 | Series introduction & major AML challenges | | 02:06 | Approach to older, fit adult with AML (Dr. Michaels) | | 05:44 | When is transplant necessary for older fit patients? | | 06:56 | Does AML always require immediate treatment? | | 08:03 | Special considerations for TP53-mutated AML in fit older adults | | 09:30 | Historical & current landscape of FLT3-mutated AML therapy (Dr. Pearl) | | 14:35 | Therapy choices for older, unfit FLT3-mutant AML patients | | 16:30 | Why no equivalent ‘targeted’ therapy for TP53-mutant AML? | | 18:00 | What would an ideal next-gen FLT3 inhibitor look like? |

Tone & Style

The discussion is collegial, thoughtful, and detail-rich, reflecting a mix of clinical pragmatism and cautious optimism. Both Dr. Michaels and Dr. Pearl candidly acknowledge ongoing uncertainties while highlighting major strides and the real-world relevance to clinical decision-making. This episode is especially felt as a resource for hematologists launching into carefully nuanced treatment discussions with their patients.

For further reading, visit bloodjournal.org.